Background In vitro, animal and epidemiological studies suggest that lipoprotein oxidation may play an important role in atherosclerosis. Antioxidants may protect against lipoprotein oxidation and in that way inhibit atherosclerosis and its clinical sequelae. To investigate this possibility, we examined the association between levels of several antioxidants and myocardial infarction using serum specimens collected 7 to 14 years before the onset of myocardial infarction.
Methods and Results A nested case-control design was used.
Cases and control subjects were selected from the 25 802
persons who had donated 15 mL of blood in 1974 for a serum bank. Cases comprised 123 persons with a subsequent first diagnosis of myocardial infarction who ranged from 23 through 58 years of age in 1974 and who had had their first diagnosis of myocardial infarction during 1981 to 1988. Two groups of control subjects matched to the cases for sex and age were selected from donors to the serum bank, one from those with hospital admissions during the same period and the other from the total group of donors. Sera were assayed for four carot-A ntioxidants are presently of interest for their potential role in inhibiting atherosclerosis, thus preventing some major clinical complications of atherosclerosis such as myocardial infarction. a-Tocopherol and several carotenoids have been shown to act as antioxidants.'-4 Specifically, a-tocopherol and P-carotene can trap free radicals by breaking the chain reaction of lipid peroxidation, a-tocopherol doing this at high oxygen concentrations and a-carotene at low oxygen concentrations (partial pressures of oxygen < 150 mm Hg).4 a-Carotene and other carotenoids found in serum, namely, lycopene, lutein, and zeaxanthin, can also quench singlet oxygen, a potential initiator of lipid peroxidation. 2, 5 In vitro experiments have demonstrated that lipid peroxidation may modify low-density lipoprotein (LDL)6 and that modified LDL may play a role in atherogenesis.6-9 The oxidatively modified LDL appears enoids (,8-carotene, lycopene, lutein, and zeaxanthin), a-tocopherol, and cholesterol. Because associations with these serum nutrients showed similar trends whether based on hospital or community controls, the two control groups were combined. There was a significantly increasing risk for subsequent myocardial infarction with decreasing levels of (3-carotene in 1974 (P value for trend, .02) and a suggestive trend with decreasing levels of lutein (P=.09). When the results were stratified by smoking status, the excess risk of myocardial infarction associated with low serum levels of carotenoids was limited to smokers. A protective association with higher levels of a-tocopherol was suggested only among persons with high levels of serum cholesterol.
Conclusions Low serum levels of carotenoids were associated with an increased risk of subsequent myocardial infarction among smokers. (Circulation. 1994; 90:1154 -1161 Key Words * antioxidants * myocardial infarction * atherosclerosis to be (1) capable of signaling monocytes to enter the arterial intima, where they undergo transformation into macrophages, (2) capable of immobilizing macrophages in tissues, possibly leading to their retention in the subendothelial space, (3) recognized by a class of macrophage scavenger receptors that rapidly endocytose modified LDL, and (4) potentially cytotoxic, injuring endothelial cells and smooth muscle cells and perhaps perpetuating infiltration of LDL into arterial intima. [7] [8] [9] As a result of these processes, foam cells may be generated with potential progression of atherosclerotic lesions.
Few epidemiological studies have examined the association between serum antioxidants and cardiovascular disease or death.10-'5 Only two have examined the association between a-carotene and these outcomes prospectively.10'5 To replicate their findings in a different population and to include the major carotenoids found in human serum, we studied prediagnostic serum levels of these carotenoids and serum a-tocopherol among 123 cases of myocardial infarction and 246 matched control subjects in Washington County, Md. 
Hospital Control Definition
Hospital control subjects were selected from individuals who were admitted to Washington County Hospital in the same year as the case to which they were matched, were the same sex as the case, were within 2 years of the case's age, and had participated in the 1974 serum collection project and the 1975 private census. Their diagnoses on discharge could not include myocardial infarction, atherosclerotic vascular disease, cerebrovascular disease, or cancer. Other exclusion criteria on hospital chart review and cancer registry were the same as for cases with the additional exclusion of persons with a history of myocardial infarction at any time preceding the time of the case's myocardial infarction. Medications for diabetes or coronary heart disease reported at the time of serum collection were also exclusion criteria.
Community Control Definition
Community control subjects were selected from the roster of participants in the 1974 serum collection project and the 1975 private census who were still residents of Washington County at the time of the matched case's admission to the hospital for myocardial infarction and were the same sex as the case and within 2 years of the case's age. Individuals were excluded as community control subjects if they had been admitted to Washington County Hospital for myocardial infarction, had been registered as having cancer, or had told the interviewer at the time of serum collection that they took medication for coronary heart disease or diabetes.
Laboratory Assays
Blood collected in 1974 was allowed to clot at room temperature and was then refrigerated at 40 to 5°C until centrifugation. The serum then was promptly frozen and stored at -70°C from 1974 until processing for this study in July 1990, 16 years later. Tubes of frozen sera from study participants were grouped in sets, each set consisting of sera from a case and its matched hospital and community control subjects. For each group of seven sets, an additional two tubes of reference serum were included to serve as quality control specimens for laboratory assays. Reference serum comprised blood collected from personnel at the Johns Hopkins Training Center. These specimens were pooled, allowed to clot at room temperature, and centrifuged; the serum was aliquotted to 36 tubes. The tubes were stored at -70°C for several days before removing all tubes to create sets. All tubes of sera from study participants and pooled blood were assigned identification numbers and shipped together on dry ice in one insulated container to the Hoffnann-La Roche Laboratory in Basel, Switzerland, where they were stored at -70°C until analyzed. The laboratory personnel did not know which tubes contained serum from cases, control subjects, or reference specimens.
During a 2-week period in July 1990, levels of cholesterol, carotenoids, and a-tocopherol were assayed. The samples were thawed for the cholesterol estimation and immediately refrozen, then thawed for the carotenoid and a-tocopherol assays and refrozen, and thawed once more for repeat assays. Up to four freeze-thaw cycles have been shown not to affect levels of carotenoids and a-tocopherol.20 Micronutrient levels were determined by high-performance liquid chromatography on reversed phase as described in detail in a recent publication.21 Each set of sera was assayed on the same day with the same reagents. The samples were protected from light the entire time.
The replicate assays of the reference sera indicated acceptable low coefficients of interassay variation (<5%) for The correlation between pairs of serum micronutrients (13-carotene, lutein, lycopene, zeaxanthin, and a-tocopherol) was assessed using data from all study participants, as were the correlations between each micronutrient and total cholesterol. Correlations >.50
were found between a-tocopherol and total cholesterol (r=.54, P=.0001) and between lutein and zeaxanthin (r=.64, P=.0001). All other correlations were weak (eg, the correlation between 1-carotene and cholesterol, r=.16).
Because the associations with serum nutrients were similar whether based on hospital or community control subjects, the two control groups were combined. Similarity of the two control groups was based on the following observations: mean levels of micronutrients in hospital and community control subjects were similar; case-control differences in micronutrient levels were in the same direction for both control groups; and doseresponse trends between serum micronutrients and myocardial infarction using hospital control subjects were similar to those obtained by using community control subjects.
Mean levels of serum antioxidants in the control subjects, stratified by level of risk factors for myocardial infarction, are shown in Table 2 . These differences were examined among control subjects for the purpose of looking at relations apart from an association with myocardial infarction, that is, to determine whether cigarette smoking, cholesterol, or blood pressure might be potential confounders of the relation between the serum micronutrients and myocardial infarction. The significance levels were set lower than usual for individual t tests (P<.01) because multiple comparisons were performed. The significance of the trend tests was essentially unchanged whether weighted or unweighted simple linear regression was performed; therefore, unweighted regression results are reported. The most notable findings were (1) significantly higher mean p-carotene levels among women than men, (2) a significant positive trend of increasing levels of lutein and a-tocopherol with increasing age, (3) lower mean levels of ,-carotene with higher levels of cigarette smoking, although differences between means did not achieve statistical significance, and the lowest mean level of lycopene among the heaviest smokers (225 cigarettes per day), which was significantly different from mean levels of lycopene in other smoking categories, a suggestive trend of decreasing levels of these micronutrients with number of cigarettes smoked, (4) a significant positive trend of higher mean levels of micronutrients with higher levels of cholesterol for all micronutrients with the exception of a-carotene and zeaxanthin, and (5) significantly higher mean levels of a-tocopherol and lutein and lower mean levels of ,8-carotene with increased systolic blood pressure. Table 3 presents a comparison of the mean levels of the micronutrients in cases and control subjects. Because the results from transformed data were not appreciably different from results using original data, the untransformed means are shown here. For all the carotenoids, the control subjects had higher mean serum levels than the cases, with the difference for ,l-carotene achieving a P value of .03. Mean serum a-tocopherol was higher in the cases than the control subjects, but the mean ratio of a-tocopherol to cholesterol was nearly the same for cases and control subjects. Mean levels of serum micronutrients were also com- Table 4 , levels of carotenoids, except lycopene, were inversely associated with myocardial infarction. The trend of increasing risk for myocardial infarction with decreasing levels of carotenoids was strongest for ,B-carotene (P=.02) and suggestive for lutein (P=.09). Persons with fl-carotene levels in the lowest quintile were more than twice as likely to have a myocardial infarction than persons with P-carotene levels in the highest quintile (odds ratio, 2.23; 95% confidence interval, 1.11 to 4.48).
In contrast, a trend of decreasing risk for myocardial infarction with decreasing levels of a-tocopherol was observed (P=.03), but not for the a-tocopherol to cholesterol ratio. To further take into account the correlation of serum a-tocopherol with cholesterol, the relation between a-tocopherol and myocardial infarction was also assessed for three strata of cholesterol levels using conditional logistic regression. As shown in Table 5 , there was an apparent interaction between cholesterol and a-tocopherol levels with respect to subsequent myocardial infarction. At low levels of a-tocopherol, there was a definite trend of increasing risk with increasing concentrations of serum cholesterol, a t.:eiid that was not observed if serum levels of a-tocopherol were above the median. Only at cholesterol levels 2240 mg/dL did low serum levels of a-tocopherol appear to be associated with the risk of myocardial infarction. Adjustment for smoking, blood pressure, or interactions between a-tocopherol and age or sex had little effect on these findings.
Because carotenoid levels were lower in smokers than nonsmokers (Table 2) , the possibility was examined that low serum carotenoid levels might merely reflect the intensity of smoking. This did not appear to be the case. For each quintile of carotenoid levels, smokers reported smoking a median of close to 20 cigarettes per day. Smoking status was entered as a covariate in conditional logistic regression models that assessed the relation between myocardial infarction and serum carotenoids. Table 6 demonstrates that smoking increased the risk of myocardial infarction regardless of carotenoid level. Among nonsmokers, there was no demonstrable association of low levels of any of the four carotenoids with myocardial infarction. In contrast, among smokers in 1974, low levels of each of the carotenoids were associated with an increased risk of subsequent myocardial infarction. Again, intensity of smoking did not appear to be an explanation for this finding. The association between carotenoid levels and myocardial infarction did tMatched analysis, adjusted for blood pressure and smoking. tMedian value for a-tocopherol among control subjects: 10.5 mg/L (after 16 years of storage). tMatched analysis, adjusted for serum cholesterol and blood pressure. *Median values for carotenoids among control subjects: 13-carotene, 16.7 ,ug/dL; lycopene, 38.5 ,ug/dL; lutein, 13.0 ,ugIdL; zeaxanthin, 3.3 ,ug/dL (after 16 years of storage).
not differ significantly among persons smoking 1 to 24 cigarettes per day and those smoking 225 cigarettes per day at baseline. When cholesterol and blood pressure levels were included in the logistic regression analysis, there were only minimal changes in the odds ratios shown in Table 6 . Additionally, accounting for the possible interactions between age and carotenoids or between sex and carotenoids caused essentially no change in the odds ratios.
Discussion
The major findings of this study were a significant trend of increasing risk for subsequent myocardial infarction associated with low levels of serum 13-carotene and a suggestive trend with low levels of serum lutein. The increased risk for myocardial infarction with low levels of carotenoids appeared to be limited to smokers. Results from other studies that examined the association between atherosclerosis-related disease or mortality and serum carotenoids without stratification by smoking status were consistent with these findings. In an ecologic study, Gey et al10 analyzed the association of serum carotene (}3-carotene and a-carotene) with ischemic heart disease mortality in 16 European populations. Groups of about 100 men, ages 40 to 49 years, were randomly sampled from each of these regions and blood samples taken. When the three Finnish populations were excluded, based on the postulate that part of the high risk for ischemic heart disease in these three populations was due to genetic differences in apolipoproteins, a significant inverse correlation between incident rate of ischemic heart disease death and the median level of plasma carotene in the groups of men from these populations was observed (r=-.71 The association of vitamin E with coronary heart disease also has been examined in other studies, but with contradictory results. In the ecologic study among European communities and the study of angina in Scotland, high levels of serum a-tocopherol were associated with a decreased risk of disease.10'11 The Health Professionals Follow-up Study24 and the Nurses Health Study27 also found that use of vitamin E supplements was associated with a decreased risk of coronary disease, and the Alpha-Tocopherol Beta Carotene Cancer Prevention Study found a nonsignificant decrease in the incidence of ischemic heart disease death among persons taking vitamin E compared with the control group. 25 However, three studies that assessed prediagnostic levels of serum a-tocopherol failed to demonstrate that high levels of serum a-tocopherol at baseline were associated with subsequent protection against coronary disease.10"13 '14 In the Basel cohort, failure to find a significant association was attributed to the high levels of a-tocopherol among the participants, with too little variability to make it possible to study the effects of low a-tocopherol levels in the serum. All quartiles of lipidstandardized a-tocopherol were above the presumed critical threshold for adverse cardiovascular events, and it was judged that all (or virtually all) participants had levels that were protective.10 In the Dutch study, persons who died from coronary heart disease had a mean serum a-tocopherol level at baseline that was only 5% lower than the mean level for control subjects.14 In the Eastern Finnish study, the cases had levels that were 5% higher on average than the control subjects,13 in agreement with the present study in which the mean prediagnostic serum level of a-tocopherol was also 5% higher among cases than among control subjects. Another reason for different outcomes among casecontrol studies could be that most control subjects will have some coronary atherosclerosis and some may even have silent ischemic heart disease. This misclassification of control subjects would lessen the difference between cases and control subjects and thereby reduce the likelihood of finding an association.
Loss of micronutrients in frozen sera over time is sometimes suggested as a reason for not being able to demonstrate an association. A recent review of longterm storage effects, however, has shown that concentrations of a-tocopherol appear to be fairly stable for at least 15 years if stored at -70°C or colder. 32 The serum for the present study was stored at -70°C for 16 years before assay. Although some loss of P-carotene did occur, the levels of serum a-tocopherol and P-carotene were both sufficiently high to demonstrate important differences between cases and control subjects. Most important, sera from each case-control set were stored, processed, and assayed similarly, so that differences between cases and control subjects could not have resulted from differences in storage or technical factors.
In this study, the numbers of cases and control subjects are sufficiently large to make it somewhat unlikely that conclusions based on the total group resulted from chance. The situation is different with respect to the stratified analyses. Even though the associations with different levels of smoking and serum cholesterol were not selected from a myriad of subgroup analyses, the number of participants in some of the stratified cells are sufficiently small to make these studies with respect to }3-carotene and a-tocopherol f findings only tentative.
Conclusions
The possibility that ,B-carotene and possibly other carotenoids may aid in preventing myocardial infarction seems worthy of further attempts at confirmation, especially as it may be related to smoking. The fact that this possibility has been raised in relatively young study populations suggests its potential usefulness in preventing premature deaths. Other ongoing trials of P-carotene supplementation, such as the Physicians Health Study33 with a primary outcome of cardiovascular disease, will help to clarify whether protection is associated with P-carotene. A study currently under way in one of the centers in the Atherosclerosis Risk In Communities (ARIC) study will indicate whether or not serum levels of antioxidants are associated with carotid artery wall thickening and/or various clotting factors. 17 The results will yield further clues to the mode of action of these potentially protective antioxidant nutrients.
